AstraZeneca (AZN)
Create an AlertAstraZeneca Enterprise Value:
66.11B for June 18, 2013AstraZeneca Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| June 18, 2013 | 66.11B |
| June 17, 2013 | 66.09B |
| June 14, 2013 | 65.88B |
| June 13, 2013 | 66.21B |
| June 12, 2013 | 66.10B |
| June 11, 2013 | 66.05B |
| June 10, 2013 | 66.63B |
| June 7, 2013 | 66.69B |
| June 6, 2013 | 66.74B |
| June 5, 2013 | 65.88B |
| June 4, 2013 | 66.44B |
| June 3, 2013 | 66.74B |
| May 31, 2013 | 66.44B |
| May 30, 2013 | 67.58B |
| May 29, 2013 | 67.73B |
| May 28, 2013 | 68.64B |
| May 24, 2013 | 67.59B |
| May 23, 2013 | 67.48B |
| May 22, 2013 | 67.81B |
| May 21, 2013 | 67.01B |
| May 20, 2013 | 66.75B |
| May 17, 2013 | 66.83B |
| May 16, 2013 | 67.16B |
| May 15, 2013 | 67.06B |
| May 14, 2013 | 66.36B |
| May 13, 2013 | 66.58B |
| May 10, 2013 | 66.80B |
| May 9, 2013 | 66.85B |
| May 8, 2013 | 66.96B |
| May 7, 2013 | 66.65B |
| May 6, 2013 | 66.90B |
| May 3, 2013 | 67.41B |
| May 2, 2013 | 66.66B |
| May 1, 2013 | 66.86B |
| April 30, 2013 | 67.28B |
| April 29, 2013 | 67.59B |
| April 26, 2013 | 66.81B |
| April 25, 2013 | 66.28B |
| April 24, 2013 | 66.69B |
| April 23, 2013 | 67.30B |
| April 22, 2013 | 66.49B |
| April 19, 2013 | 66.40B |
| April 18, 2013 | 66.20B |
| April 17, 2013 | 65.88B |
| April 16, 2013 | 66.28B |
| April 15, 2013 | 65.96B |
| April 12, 2013 | 66.53B |
| April 11, 2013 | 66.34B |
| April 10, 2013 | 66.13B |
| April 9, 2013 | 65.60B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
AZN Enterprise Value Benchmarks
| Companies | |
|---|---|
| GlaxoSmithKline | 153.47B |
| Pfizer | 211.90B |
| Merck | 151.84B |
AZN Enterprise Value Rankings
| Overall |
98th percentile 172 of 16770 |
| Sector |
98th percentile 18 of 1408 in Healthcare |
| Industry |
91st percentile 11 of 135 in Drug Manufacturers - Major |
AZN Enterprise Value Range, Past 5 Years
| Minimum | 40.64B | Mar 9 2009 |
| Maximum | 82.91B | Aug 5 2008 |
| Average | 64.30B |
